NUTRA PHARMA CORP
Close on Oct 19, 2026
- Market cap
- $806.69K
- P/E (TTM)
- –
- Dividend yield
- –
About Nutra Pharma
Medicinal Chemicals & Botanical Products, SIC 2833
Nutra Pharma Corp. is a biopharmaceutical company focused on the acquisition, licensing, and commercialization of pharmaceutical technologies, homeopathic treatments, and ethical drugs. Its research and development efforts target products for autoimmune conditions, neurological disorders, viral infections, and chronic pain management. The company's consumer offering includes over-the-counter pain relief remedies such as Nyloxin, Pet Pain-Away for cats and dogs, Equine Pain-Away for horses, and Luxury Feet for footwear-related discomfort. In addition to its consumer formulations, the company serves third-party distributors and partners, such as Avini Health, by providing formulation and contract manufacturing services for private-label goods and dietary supplements.
Nutra Pharma manages drug discovery research and clinical development while operating in-house manufacturing facilities to produce its product portfolio. The company conducts business domestically and pursues international market distribution for its branded health and pain relief products. Nutra Pharma maintains its principal executive offices in Boca Raton, Florida.
Summary of the business section of Nutra Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NUTRA PHARMA CORP
- Founded
- 2000
- Headquarters
- Boca Raton, FL
- Address
- 6400 Park Of Commerce Blvd, Suite 1b 33487
- Phone
- (954) 509-0911
- Employees
- 7, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- California
- Fiscal year ends
- December 31
- Auditor
- Astra Audit & Advisory, Tampa, Florida
Stock & identifiers
- Ticker
- NPHC
- Exchange
- OTC
- Shares outstanding
- 7.16B, Aug 19, 2026
- Public float
- $702.70K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, May 19, 2015; 1-for-40 reverse, May 18, 2015
- SEC CIK
- 1119643
- CUSIP
- 67060U208
- ISIN
- US67060U2087
- EIN
- 91-2021600
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Nutra Pharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“We employ a total of 7 employees, consisting of: (a) our Chief Executive Officer (b) Our Director of Marketing (c) our Chief Scientific”
Corporate history
Events identified from SEC filings